Symphogen captures the diversity and specificity of the natural immune response in rationally designed recombinant antibody compositions.
Vision
Symphogen’s vision is to create superior antibody therapeutics by decoding the wisdom of nature.
Mission
With its pioneering antibody discovery and manufacturing technologies, Symphogen aims to create, develop, manufacture and commercialize target-specific recombinant antibodies that mimic the natural diversity and specificity of the human immune response. Symphogen is building a proprietary product pipeline within several disease areas including infectious diseases and cancer.
Symphogen’s Sym004 product exhibits superior anti-cancer efficacy in vivo in a range of tumor xenograft models as compared to marketed monoclonal anti-EGFR antibodies by a mechanism of action that is distinct from that of monoclonal antibodies.
Symphogen was founded in 2000 and is backed by a leading international venture capital investor syndicate.
Symphogen’s headquarters are located in Copenhagen, Denmark. Symphogen has recently opened its US office in Princeton, New Jersey.
